within Pharmacolibrary.Drugs.ATC.N;

model N02CA04
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.13,
    Cl             = 0.0005,
    adminDuration  = 600,
    adminMass      = 2 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.005,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0011666666666666668,
    Tlag           = 600
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>N02CA04</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Methysergide is an ergot alkaloid-derived serotonin antagonist formerly used in the prophylactic treatment of migraine and cluster headaches. Due to risks of fibrotic complications (retroperitoneal, pulmonary, and cardiac valvulopathy), its clinical use is now extremely limited or unavailable in many countries.</p><h4>Pharmacokinetics</h4><p>Estimated pharmacokinetic parameters based on general ergot alkaloid properties, as no published clinical pharmacokinetic studies with indexed values for methysergide in humans were found.</p><h4>References</h4><ol><li><p>Bredberg, U, et al., &amp; Tfelt-Hansen, V (1986). Pharmacokinetics of methysergide and its metabolite methylergometrine in man. <i>European journal of clinical pharmacology</i> 30(1) 75–77. DOI:<a href=\"https://doi.org/10.1007/BF00614199\">10.1007/BF00614199</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/3709634/\">https://pubmed.ncbi.nlm.nih.gov/3709634</a></p></li><li><p>Eadie, MJ (2001). Clinically significant drug interactions with agents specific for migraine attacks. <i>CNS drugs</i> 15(2) 105–118. DOI:<a href=\"https://doi.org/10.2165/00023210-200115020-00003\">10.2165/00023210-200115020-00003</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/11460889/\">https://pubmed.ncbi.nlm.nih.gov/11460889</a></p></li><li><p>Kahn, RS, et al., &amp; van Praag, HM (1990). Effects of serotonin antagonists on m-chlorophenylpiperazine-mediated responses in normal subjects. <i>Psychiatry research</i> 33(2) 189–198. DOI:<a href=\"https://doi.org/10.1016/0165-1781(90)90073-e\">10.1016/0165-1781(90)90073-e</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/2243896/\">https://pubmed.ncbi.nlm.nih.gov/2243896</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end N02CA04;
